🇺🇸 FDA
Pipeline program

Pozelimab

R3918-PLE-2399

Approved small_molecule active

Quick answer

Pozelimab for CHAPLE Disease is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
CHAPLE Disease
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials